Literature DB >> 32852845

N-glycome analysis detects dysglycosylation missed by conventional methods in SLC39A8 deficiency.

Julien H Park1,2, Robert G Mealer3,4,5, Abdallah F Elias6,7, Susanne Hoffmann8, Marianne Grüneberg2, Saskia Biskup9, Manfred Fobker10, Jaclyn Haven6, Ute Mangels2, Janine Reunert2, Stephan Rust2, Jonathan Schoof6, Corbin Schwanke6, Jordan W Smoller3,4, Richard D Cummings5, Thorsten Marquardt2.   

Abstract

Congenital disorders of glycosylation (CDG) are a growing group of inborn metabolic disorders with multiorgan presentation. SLC39A8-CDG is a severe subtype caused by biallelic mutations in the manganese transporter SLC39A8, reducing levels of this essential cofactor for many enzymes including glycosyltransferases. The current diagnostic standard for disorders of N-glycosylation is the analysis of serum transferrin. Exome and Sanger sequencing were performed in two patients with severe neurodevelopmental phenotypes suggestive of CDG. Transferrin glycosylation was analyzed by high-performance liquid chromatography (HPLC) and isoelectric focusing in addition to comprehensive N-glycome analysis using matrix-assisted laser desorption ionization time of flight (MALDI-TOF) mass spectrometry (MS). Atomic absorption spectroscopy was used to quantify whole blood manganese levels. Both patients presented with a severe, multisystem disorder, and a complex neurological phenotype. Magnetic resonance imaging (MRI) revealed a Leigh-like syndrome with bilateral T2 hyperintensities of the basal ganglia. In patient 1, exome sequencing identified the previously undescribed homozygous variant c.608T>C [p.F203S] in SLC39A8. Patient 2 was found to be homozygous for c.112G>C [p.G38R]. Both individuals showed a reduction of whole blood manganese, though transferrin glycosylation was normal. N-glycome using MALDI-TOF MS identified an increase of the asialo-agalactosylated precursor N-glycan A2G1S1 and a decrease in bisected structures. In addition, analysis of heterozygous CDG-allele carriers identified similar but less severe glycosylation changes. Despite its reliance as a clinical gold standard, analysis of transferrin glycosylation cannot be categorically used to rule out SLC39A8-CDG. These results emphasize that SLC39A8-CDG presents as a spectrum of dysregulated glycosylation, and MS is an important tool for identifying deficiencies not detected by conventional methods.
© 2020 The Authors. Journal of Inherited Metabolic Disease published by John Wiley & Sons Ltd on behalf of SSIEM.

Entities:  

Keywords:  MALDI-TOF MS; SLC39A8; congenital disorders of glycosylation; glycosylation; manganese

Year:  2020        PMID: 32852845      PMCID: PMC8086894          DOI: 10.1002/jimd.12306

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  35 in total

1.  Integrating mass spectrometry-based plasma (or serum) protein N-glycan profiling into the clinical practice?

Authors:  Arnaud Bruneel; François Fenaille
Journal:  Ann Transl Med       Date:  2019-09

Review 2.  Nutritional aspects of manganese from experimental studies.

Authors:  C L Keen; J L Ensunsa; M H Watson; D L Baly; S M Donovan; M H Monaco; M S Clegg
Journal:  Neurotoxicology       Date:  1999 Apr-Jun       Impact factor: 4.294

Review 3.  The galactosyltransferase family.

Authors:  T Hennet
Journal:  Cell Mol Life Sci       Date:  2002-07       Impact factor: 9.261

4.  Multiple phenotypes in phosphoglucomutase 1 deficiency.

Authors:  Laura C Tegtmeyer; Stephan Rust; Monique van Scherpenzeel; Bobby G Ng; Marie-Estelle Losfeld; Sharita Timal; Kimiyo Raymond; Ping He; Mie Ichikawa; Joris Veltman; Karin Huijben; Yoon S Shin; Vandana Sharma; Maciej Adamowicz; Martin Lammens; Janine Reunert; Anika Witten; Esther Schrapers; Gert Matthijs; Jaak Jaeken; Daisy Rymen; Tanya Stojkovic; Pascal Laforêt; François Petit; Olivier Aumaître; Elzbieta Czarnowska; Monique Piraud; Teodor Podskarbi; Charles A Stanley; Reuben Matalon; Patricie Burda; Soraya Seyyedi; Volker Debus; Piotr Socha; Jolanta Sykut-Cegielska; Francjan van Spronsen; Linda de Meirleir; Pietro Vajro; Terry DeClue; Can Ficicioglu; Yoshinao Wada; Ron A Wevers; Dieter Vanderschaeghe; Nico Callewaert; Ralph Fingerhut; Emile van Schaftingen; Hudson H Freeze; Eva Morava; Dirk J Lefeber; Thorsten Marquardt
Journal:  N Engl J Med       Date:  2014-02-06       Impact factor: 91.245

5.  Transferrin variants: pitfalls in the diagnostics of Congenital disorders of glycosylation.

Authors:  Andrea Zühlsdorf; Julien Heinrich Park; Yoshinao Wada; Stephan Rust; Janine Reunert; Ingrid DuChesne; Marianne Grüneberg; Thorsten Marquardt
Journal:  Clin Biochem       Date:  2014-10-08       Impact factor: 3.281

Review 6.  Glycobiology and schizophrenia: a biological hypothesis emerging from genomic research.

Authors:  Robert G Mealer; Sarah E Williams; Mark J Daly; Edward M Scolnick; Richard D Cummings; Jordan W Smoller
Journal:  Mol Psychiatry       Date:  2020-05-06       Impact factor: 15.992

Review 7.  3D Structure and Function of Glycosyltransferases Involved in N-glycan Maturation.

Authors:  Masamichi Nagae; Yoshiki Yamaguchi; Naoyuki Taniguchi; Yasuhiko Kizuka
Journal:  Int J Mol Sci       Date:  2020-01-09       Impact factor: 5.923

8.  A missense variant in SLC39A8 is associated with severe idiopathic scoliosis.

Authors:  Gabe Haller; Kevin McCall; Supak Jenkitkasemwong; Brooke Sadler; Lilian Antunes; Momchil Nikolov; Julia Whittle; Zachary Upshaw; Jimann Shin; Erin Baschal; Carlos Cruchaga; Matthew Harms; Cathleen Raggio; Jose A Morcuende; Philip Giampietro; Nancy H Miller; Carol Wise; Ryan S Gray; Lila Solnica-Krezel; Mitchell Knutson; Matthew B Dobbs; Christina A Gurnett
Journal:  Nat Commun       Date:  2018-10-09       Impact factor: 14.919

Review 9.  SLC39A8 gene encoding a metal ion transporter: discovery and bench to bedside.

Authors:  Daniel W Nebert; Zijuan Liu
Journal:  Hum Genomics       Date:  2019-09-14       Impact factor: 4.639

10.  The schizophrenia risk locus in SLC39A8 alters brain metal transport and plasma glycosylation.

Authors:  Robert G Mealer; Bruce G Jenkins; Chia-Yen Chen; Mark J Daly; Tian Ge; Sylvain Lehoux; Thorsten Marquardt; Christopher D Palmer; Julien H Park; Patrick J Parsons; Robert Sackstein; Sarah E Williams; Richard D Cummings; Edward M Scolnick; Jordan W Smoller
Journal:  Sci Rep       Date:  2020-08-04       Impact factor: 4.379

View more
  2 in total

Review 1.  Systematic Review: Drug Repositioning for Congenital Disorders of Glycosylation (CDG).

Authors:  Sandra Brasil; Mariateresa Allocca; Salvador C M Magrinho; Inês Santos; Madalena Raposo; Rita Francisco; Carlota Pascoal; Tiago Martins; Paula A Videira; Florbela Pereira; Giuseppina Andreotti; Jaak Jaeken; Kristin A Kantautas; Ethan O Perlstein; Vanessa Dos Reis Ferreira
Journal:  Int J Mol Sci       Date:  2022-08-05       Impact factor: 6.208

2.  Clinical, molecular and glycophenotype insights in SLC39A8-CDG.

Authors:  Eleonora Bonaventura; Rita Barone; Luisa Sturiale; Rosa Pasquariello; Maria Grazia Alessandrì; Anna Maria Pinto; Alessandra Renieri; Celeste Panteghini; Barbara Garavaglia; Giovanni Cioni; Roberta Battini
Journal:  Orphanet J Rare Dis       Date:  2021-07-10       Impact factor: 4.123

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.